Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Lafayette

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|June 11, 2026
Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION TrialKieran McCafferty, Jonathan Barratt, Yusuke Suzuki, et al.
Kidney International Reports|August 11, 2020
Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental GlomerulosclerosisDebbie S Gipson, Michelle A Hladunewich, Richard Lafayette, et al.
Pediatric Nephrology (Berlin, Germany)|April 26, 2024
Growth in children with nephrotic syndrome: a post hoc analysis of the NEPTUNE studyAesha Maniar, Debbie S Gipson, Tammy Brady, et al.
Pediatric Nephrology (Berlin, Germany)|February 6, 2024
Longitudinal analysis of blood pressure and lipids in childhood nephrotic syndromeJohnathon Carboni, Elizabeth Thomas, Debbie S Gipson, et al.
The New England Journal of Medicine|November 6, 2025
A Phase 3 Trial of Atacicept in Patients with IgA NephropathyRichard Lafayette, Sean J Barbour, Robert M Brenner, et al.
Lancet (London, England)|June 4, 2026
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trialHiddo J L Heerspink, Meg J Jardine, Donald E Kohan, et al.
The New England Journal of Medicine|November 10, 2025
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 TrialVlado Perkovic, Hernán Trimarchi, Vladimir Tesar, et al.
Contemporary Clinical Trials Communications|April 14, 2021
Improving data quality in observational research studies: Report of the Cure Glomerulonephropathy (CureGN) networkBrenda W Gillespie, Louis-Philippe Laurin, Dawn Zinsser, et al.
Glomerular Diseases|November 1, 2021
Racial-ethnic differences in health-related quality of life among adults and children with glomerular diseaseJill R Krissberg, Margaret E Helmuth, Salem Almaani, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 3, 2022
Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular DiseaseJill R Krissberg, Michelle M O'Shaughnessy, Abigail R Smith, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Clinical Journal of the American Society of Nephrology : CJASN|June 11, 2026
Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION TrialKieran McCafferty, Jonathan Barratt, Yusuke Suzuki, et al.
Kidney International Reports|August 11, 2020
Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental GlomerulosclerosisDebbie S Gipson, Michelle A Hladunewich, Richard Lafayette, et al.
Pediatric Nephrology (Berlin, Germany)|April 26, 2024
Growth in children with nephrotic syndrome: a post hoc analysis of the NEPTUNE studyAesha Maniar, Debbie S Gipson, Tammy Brady, et al.
Pediatric Nephrology (Berlin, Germany)|February 6, 2024
Longitudinal analysis of blood pressure and lipids in childhood nephrotic syndromeJohnathon Carboni, Elizabeth Thomas, Debbie S Gipson, et al.
The New England Journal of Medicine|November 6, 2025
A Phase 3 Trial of Atacicept in Patients with IgA NephropathyRichard Lafayette, Sean J Barbour, Robert M Brenner, et al.
Lancet (London, England)|June 4, 2026
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trialHiddo J L Heerspink, Meg J Jardine, Donald E Kohan, et al.
The New England Journal of Medicine|November 10, 2025
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 TrialVlado Perkovic, Hernán Trimarchi, Vladimir Tesar, et al.
Contemporary Clinical Trials Communications|April 14, 2021
Improving data quality in observational research studies: Report of the Cure Glomerulonephropathy (CureGN) networkBrenda W Gillespie, Louis-Philippe Laurin, Dawn Zinsser, et al.
Glomerular Diseases|November 1, 2021
Racial-ethnic differences in health-related quality of life among adults and children with glomerular diseaseJill R Krissberg, Margaret E Helmuth, Salem Almaani, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 3, 2022
Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular DiseaseJill R Krissberg, Michelle M O'Shaughnessy, Abigail R Smith, et al.
Pageof 5